Su Wang

Su Wang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JHJiayi Hao
Jiayi Hao
CTChunbian Tang
Chunbian Tang
QYQingqing Yang
Qingqing Yang
YGYouyou Gu
Youyou Gu
SWSu Wang
Su Wang
BZBaoqi Zeng Zeng
Baoqi Zeng Zeng
Previous studies have shown that diabetes is linked to both low muscle strength and abdominal obesity. However, the combined relationship and synergistic effect on the risk of diabetes in middle-aged and elderly people are still unclear. Using nationally representative data collected between 2011 and 2020 by the China Health and Retirement Longitudinal Study (CHARLS). Dynapenic abdominal obesity was a measure that combined hand grip strength and waist circumference. 7934 participants aged ≥ 45 years were divided into four groups (neither dynapenia nor abdominal obesity, only dynapenia, only abdominal obesity, and dynapenic abdominal obesity). Cox proportional hazards models were used to calculate the association of dynapenic abdominal obesity on diabetes. The reference group comprised participants with neither dynapenia nor abdominal obesity. Dynapenic abdominal obesity was associated with an increased risk of diabetes (HR = 1.52; 95%CI = 1.12–2.05). Only abdominal obesity group also had a higher risk of diabetes (HR = 1.54, 95%CI = 1.32–1.80), and only dynapenia was not statistically associated with the risk of diabetes (HR = 1.05, 95%CI = 0.80–1.39) and sensitivity analysis showed that the results were robust. Dynapenic abdominal obesity and only abdominal obesity might be associated with 52% and 54% higher risk of diabetes, while only dynapenia was not statistically associated with the risk of diabetes.

4 April 2025 in Metabolic Brain Disease
Verified
Journal Article
Open access
PDF file
XHXiangli Han
Xiangli Han
GHGuoping He
Guoping He
JWJuanjuan Wang
Juanjuan Wang
HLHanxi Lou
Hanxi Lou
LCLei Chen
Lei Chen
LGLiping Guo
Liping Guo
Xifeng Jiannao Pill (XFJNP), a traditional Chinese medicine formulation, has been shown to alleviate clinical symptoms in patients with Parkinson’s disease (PD). However, the underlying mechanisms remain unclear. Therefore, this study employs network pharmacology and molecular biology to investigate the potential therapeutic mechanisms of XFJNP. Firstly, network pharmacology is utilized to screen the major active ingredients and potential targets of XFJNP in the treatment of PD. Following this, pathway enrichment analysis is conducted to gain insights into the underlying mechanisms. Secondly, an MPP+-induced SH-SY5Y cell model and an MPTP-induced PD mouse model to investigate the therapeutic effects and potential mechanisms of XFJNP on PD. By assessing apoptosis, oxidative stress (OS), inflammation, activation of the MAPK pathway, and conducting behavioral tests in mice, we aimed to elucidate the efficacy and underlying mechanisms of XFJNP in treating PD. Network pharmacology analysis indicates that the MAPK signaling pathway holds a key position in mediating the therapeutic effects of XFJNP for PD. In basic experimental studies, XFJNP significantly enhanced the survival rate of MPP+-induced SH-SY5Y cells in vitro, reduced OS and inflammation levels, and increased the expression of tyrosine hydroxylase (TH) protein. In the MPTP-induced PD mouse model, XFJNP effectively improved motor function and reduced the loss of dopaminergic (DA) neurons. Mechanistic studies suggest that XFJNP may mitigate OS and inflammatory responses in the substantia nigra by inhibiting the excessive activation of ERK, JNK, and p38 in the MAPK signaling pathway. Based on the results of network pharmacology analysis and experimental validation, XFJNP displays profound neuroprotective efficacy by modulating the MAPK signaling cascade, markedly diminishing neuroinflammation and mitigating OS-triggered apoptosis of DA neurons in PD models. Graphical Abstract

1 January 2022 in Public Health
Verified
Journal Article
Closed access
DLD. Liu
D. Liu
JYJ. Yang
J. Yang
SWSu Wang
Su Wang

28 November 2021 in World Chinese Journal of Digestology
Verified
Journal Article
Open access
YGYou-You Gu
You-You Gu
JWJue-Lei Wang
Jue-Lei Wang
ZCZong-Nan Chen
Zong-Nan Chen
SWSu Wang
Su Wang
XLXiaozhi Liu
Xiaozhi Liu
液体复苏是急性胰腺炎治疗的最重要的措施之一, 生理盐水及乳酸钠林格液是临床常用晶体液. 生理盐水价格便宜、易储藏, 且应用经验丰富. 乳酸钠林格液化学成分更接近于细胞外液, 能有效补充机体的水份和电解质, 减轻机体损伤, 并可以减少肾脏替代治疗. 近年来有多项研究结果发现, 应用乳酸钠林格液或生理盐水进行液体复苏的的优越性尚存在一定争议. 比较乳酸钠林格液和生理盐水治疗急性胰腺炎的疗效. 计算机检索维普、中国知网、万方、Web of Science、PubMed数据库, 检索时限截止至2020-12. 进行资料提取后, 采用RevMan 5.4软件进行统计分析. 最终共纳入文献5篇, 包括乳酸钠林格液组162例, 生理盐水组189例. 分析结果显示, 乳酸钠林格液组的ICU住院率显著小于生理盐水组(OR = 0.33, 95%CI: 0.13-0.81, P = 0.02); 而在住院天数(MD = -0.59, 95%CI: -1.26-0.08, P = 0.08)、死亡率(OR = 1.39, 95%CI: 0.44-4.40, P = 0.57)、24 h内出现全身炎症反应综合症(OR = 0.73, 95%CI: 0.41-2.33, P = 0.28)及胰腺坏死(OR = 0.71, 95%CI: 0.35-1.45, P = 0.35)方面, 两组无统计学差异. 与生理盐水相比, 在急性胰腺炎时应用乳酸钠林格液进行液体复苏可减少ICU住院率; 但乳酸钠林格液治疗急性胰腺炎在住院天数、死亡率、24小时内出现全身炎症反应综合症及胰腺坏死方面与生理盐水无明显差别.

1 January 2020 in Chinese Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
SWSu Wang
Su Wang
YZYoulu Zhang
Youlu Zhang
YBYanyan Ba
Yanyan Ba
JZJingyu Zhang
Jingyu Zhang
DSDemei Sun
Demei Sun

1 May 2021 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
CWChris Wingrove
Chris Wingrove
JHJessica Hicks
Jessica Hicks
SRSean Regan
Sean Regan
SWSu Wang
Su Wang